Archive for October, 2008

Prilosec May Blunt Plavix Benefit

Friday, October 31st, 2008

Jan 14, 2008 — Prilosec and other PPI acid-reducing drugsprevent gastric
bleeding in stent patients on Plavix — but the drugs may block Plavix’s lifesaving
anticlot action.

This suggestion comes from a small
study of…

Simple Effective Strategies for Acid Reflux Relief

Wednesday, October 29th, 2008

Prescription and Over the Counter Drugs

Many over the counter drugs are effective for mild to moderate acid reflux. These include antacids which are proven to neutralize stomach acids. Tums and Rolaids ar…

News: Progenics and Wyeth Obtain FDA Nod for Drug to Treat Opioid …

Monday, October 27th, 2008

FDA gave Progenics Pharmaceuticals and Wyeth Pharmaceuticals the go-ahead to market Relistor for opioid-induced constipation. Under the agreement established between the companies in December 2005, Pr…

Market Wire - MIV Therapeutics Featured in Scientific American Online

Wednesday, October 22nd, 2008

Upstate New Yorkers are spending a lot of money on prescription drugs, according to a new report from Excellus BlueCross BlueShield, the region’s largest health in-surer.
Of the more than 3,000 drugs prescribed in Upstate in 2007, 10 brand-name drugs accounte…

Five Common Acid Reflux Prescription Medications

Tuesday, October 21st, 2008

Most medications for heartburn only need to be taken for a short amount of time to help with the damage to the esophagus. Discovering the right acid reflux prescription medications can often be easy, and your …

Better Nutrition - Antacids may contribute to hip fractures

Saturday, October 18th, 2008

PEOPLE TAKING PROTON PUMP INHIBITORS (PPIs), common drugs used to reduce stomach acid, may be at a higher risk for breaking their bones as they age. A new study from Great Britain followed the medical records of 13,556 people with hip fractures…

NJBIZ - Drug Companies Under the Lens

Wednesday, October 15th, 2008

RALEIGH, N.C. — Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced that the Company has entered into a co-promotion agreement with ALTANA Pharma US, Inc. to promote XIFAXAN(TM) (rifaximin) tablets 200 mg.
Under the terms of the agreement, ALTANA Pharma US will utilize one of its sales forces with approximately 250 representatives to promote XIFAXAN to th…

BIOTECH Patent News - Wyeth and Nycomed announce court denial of preliminary injunction.

Sunday, October 12th, 2008

Wyeth (Madison, NJ) and its business partner Nycomed GmbH, said the United States District Court for the District of New Jersey denied Wyeth’s and Nycomed’s motion for a preliminary injunction against Teva Pharmaceuticals USA, Inc. and Sun Pharmaceuticals, …

Chain Drug Review - Top 100 pharmaceutical products *.(RX/BRANDED DRUGS)(Statistical table)

Thursday, October 9th, 2008

Top 100 Pharmaceutical Products *

LABELER DRUG NAME TOTAL Rx DOLLARS

AstraZeneca Nexium $3,456,445,872.82
Tap Pharm. Prevacid $2,721,601,826.58
Pfizer US Pharm. Lipitor $2,630,394,978.23
Pfizer US Pharm.

Related Results

Business Wire - Research and Markets: Analyze How Wyeth Will Perform in Light of Patent Expiry for the Key Effexor and Protonix Franchises Prior to 2012

Monday, October 6th, 2008

DUBLIN, Ireland — Research and Markets (http://www.researchandmarkets.com/reports/c81885) has announced the addition of Wyeth: PharmaVitae Profile to their offering.
This analysis examines the historical and forecast performance for Wyeth in the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performanc…